ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Termination for Intrauterine Fetal Death

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00141895
Recruitment Status : Terminated (Difficulty recruiting)
First Posted : September 2, 2005
Last Update Posted : July 19, 2013
Sponsor:
Information provided by (Responsible Party):
Anwar Nassar, American University of Beirut Medical Center

Brief Summary:

Misoprostol (Cytotec®) is a synthetic prostaglandin E1 analog that has been marketed in the United States since 1988 as a gastric cytoprotective agent. Despite a focused campaign by the manufacturer to curtail its use in obstetric practice, misoprostol has, over the past several years, gained widespread acceptance to effect the medical termination of pregnancy in the second trimester, either alone or after pretreatment with mifepristone. The primary reasons for this prompt incorporation into standard practice include its low cost and the lack of stringent storage requirements.

Vaginal administration seems to be more efficacious than when given orally. The use of sublingual misoprostol for first trimester abortions has been extensively investigated as evidenced by the large number of publications comparing sublingual to other routes of misoprostol for first trimester pregnancy termination, on the assumption that the sublingual route would have a similar efficacy of the vaginal route. In addition, the sublingual route would combine an easier administration with the added advantage of no restriction of mobility after administration. There has been no previous report in the literature comparing the use of misoprostol given sublingually to that given vaginally for the second trimester termination following intrauterine fetal death. Our aim is to compare efficacy, safety and patient satisfaction with misoprostol given vaginally (the current standard) to that given sublingually.


Condition or disease Intervention/treatment Phase
Labor Induction Drug: Misoprostol Phase 3

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Trial of Two Regimens of Misoprostol for Second Trimester Intrauterine Fetal Death
Study Start Date : September 2004
Actual Primary Completion Date : October 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stillbirth
Drug Information available for: Misoprostol
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: A
Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
Drug: Misoprostol
2 tablets 200 micrograms Vaginal route
Other Name: Cytotec
Active Comparator: B
Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery
Drug: Misoprostol
2 tablets of 200 micrograms Sublingual route
Other Name: Cytotec



Primary Outcome Measures :
  1. -The main outcome measures will be the induction time, defined as the time from placement of the first dose of misoprostol until the time of delivery of the fetus. [ Time Frame: 48 hours ]

Secondary Outcome Measures :
  1. The entry characteristics of the patients, including age, height, weight, parity, gestational age at induction, indication for the induction, and cervical score before the start of the induction [ Time Frame: 48 hours ]
  2. The delivery rate within 24 hours of prostaglandin commencement [ Time Frame: 48 hours ]
  3. Number of doses of misoprostol given [ Time Frame: 48 hours ]
  4. Number of unsuccessful inductions [ Time Frame: 48 hours ]
  5. Length of hospital stay [ Time Frame: 48 hours ]
  6. Need for surgical intervention to remove the placenta [ Time Frame: 24 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 14 and 24 weeks of gestation
  • Both nulliparous and multiparous women
  • An unfavorable cervix (Bishop's score less than 8)

Exclusion Criteria:

  • Known contraindications to the use of prostaglandins (e.g. asthma)
  • Previous uterine scar (previous cesarean or myomectomy where the endometrial cavity was entered)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00141895


Locations
Lebanon
American University of Beirut Medical Center
Beirut, Lebanon
Sponsors and Collaborators
American University of Beirut Medical Center
Investigators
Principal Investigator: Anwar H Nassar, MD American University of Beirut Medical Center

Responsible Party: Anwar Nassar, professor, American University of Beirut Medical Center
ClinicalTrials.gov Identifier: NCT00141895     History of Changes
Other Study ID Numbers: OGY.AN.03
First Posted: September 2, 2005    Key Record Dates
Last Update Posted: July 19, 2013
Last Verified: July 2013

Keywords provided by Anwar Nassar, American University of Beirut Medical Center:
Intrauterine fetal death, 2nd trimester, induction

Additional relevant MeSH terms:
Misoprostol
Fetal Death
Stillbirth
Pregnancy Complications
Death
Pathologic Processes
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Oxytocics